# DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct07705919/  
OnCo record `nct07705919` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of fluorouracil (5-FU), gemcitabine, fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid) and other drugs in pancreatic cancer, run by Ohio State University Comprehensive Cancer Center, not yet recruiting.

## Summary

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07705919 by Ohio State University Comprehensive Cancer Center, with a registry enrolment figure of 50 participants, started 2026-09-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biospecimen Collection; Computed Tomography; Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Fluorouracil; Gadolinium-Chelate; Gemcitabine; Irinotecan; Leucovorin Calcium; Nab-paclitaxel; Oxaliplatin; Point-of-care portable perfusion phantom (P4). Conditions listed: Borderline Resectable Pancreatic Ductal Adenocarcinoma. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: "* Histological or cytological evidence of pancreatic adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07705919
- Phase: 1/2
- Setting: DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
- Sponsor: Ohio State University Comprehensive Cancer Center
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07705919: https://clinicaltrials.gov/study/NCT07705919

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07705919.json